Dr Bristi Basu
Dr Bristi Basu is pleased to consider applications from prospective PhD students.
My research focus is in drug development and I translate preclinical findings on lead candidate agents into early phase clinical trials of novel therapeutic drugs as chief investigator, principal investigator and co-investigator in academic-led and industry-sponsored Phase I, II and III clinical trials, including first-in-human studies. My tumour site-specific focus is in hepato-pancreatico-biliary cancers, for which I am designing novel clinical trials based on preclinical research that has been performed at the Cambridge Pancreatic Cancer Centre. I am involved in projects of non-invasive imaging techniques that evaluate pharmacodynamic effects or show potential as early predictors for efficacy of anticancer drugs.
Symplectic Elements feed provided by Research Information, University of Cambridge
*Basu B, *Krebs MG, *Sundar R, Wilson RH, Spicer J, Jones R, Brada M, Talbot DC, Steele N, Ingles Garces AH, Brugger W, Harrington EA, Evans J, Hall E, Tovey H, de Oliveira FM, Carreira S, Swales K, Ruddle R, Raynaud FI, Purchase B, Dawes JC, Parmar M, Turner AJ, Tunariu N, Banerjee S, de Bono JS, Banerji U. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Ann Oncol. 2018 Sep 1;29(9):1918-1925. doi: 10.1093/annonc/mdy245 * joint 1st authors
N Cook, B Basu, D-M Smith, A Gopinathan, J Evans, W Steward, D Palmer, D Propper, B Venugopal, M Hategan, A Anthoney, L Hampson, M Nebozhyn, D Tuveson, H Farmer-Hall, H Turner, R McLeod, S Halford, D Jodrell “A Phase I trial of the ɣ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma” British Journal of Cancer 2018 Feb 13. doi: 10.1038/bjc.2017.495
FM Walter, K Mills, S Mendonca, G Abel, B Basu, N Carroll, S Ballard, J Lancaster, W Hamilton, GP Rubin, JD Emery. “Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer: a prospective cohort study” The Lancet Gastroenterology & Hepatology 2016 1: 298–306 http://dx.doi.org/10.1016/S2468-1253(16)30079-6
B Basu*, E Dean*, M Puglisi, A Greystoke, M Ong, W Burke, M Cavallin, G Bigley, C Womack, E A Harrington, S Green, E Oelmann, J S de Bono, M Ranson, U Banerji. “First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor, AZD2014” Clinical Cancer Research *Joint first authors 2015 Aug 1;21(15):3412-9
B Basu, P Correa-Sampaio, H Mohammed, M Fogarasi, W English, N Watkins, P Corrie, W Ouwehand, G Murphy. “Inhibition of MT1-MMP activity using functional antibody fragments selected against its hemopexin domain” International Journal of Biochemistry and Cell Biology 2012 Feb; 44(2): 393-403.